Eli Lilly Cuts Price of Insulin in the Wake of the Coronavirus
Eli Lilly (NYSE: LLY) is giving diabetes patients in the U.S. a break. The pharmaceutical giant is capping the out-of-pocket cost of most of its insulins to $35 per month to help ease the financial burden on diabetics who might be facing financial challenges due to the SARS-CoV-2 coronavirus outbreak.
This cap will apply to both patients who hold commercial health insurance and those who have no insurance coverage. Those covered under government insurance plans such as Medicaid and Medicare will not be eligible for the discounted price.
Image source: Getty Images.
Source Fool.com